Progen Pharmaceuticals Warrants Approved for Listing on NASDAQ
25 Julio 2007 - 5:00AM
PR Newswire (US)
Trading Will Commence July 26, 2007 Under the Ticker Symbol 'PGLAW'
BRISBANE, Australia, July 25 /PRNewswire-FirstCall/ -- Progen
Pharmaceuticals Limited (ASX:PGL)(NASDAQ:PGLA) today announced that
its warrants, which were issued in connection with the Company's
recently closed entitlements offering, have been approved for
listing on the NASDAQ Capital Market. Progen has been advised that
the warrants will commence trading on the NASDAQ Capital Market
under the ticker symbol "PGLAW", effective at market open on July
26, 2007. In order to exercise rights under the warrants, you must
pay the warrant agent the warrant exercise price equal to the U.S.
dollar equivalent of A$8.40 per share on the date of exercise,
converted using the average interbank rate on the date of payment.
The right to purchase shares by exercise of the warrants may be
exercised at any time during the period expiring on May 28, 2010 at
5:00 PM EDT. To complete the transfer between the NASDAQ and ASX
exchanges or vice versa, the holder of the warrants must fill out a
transfer form and file the document with Progen's transfer agent
Computershare, who will then place the warrants on the control
account and inform the receiving country of the additional
warrants, along with the relevant details regarding allocation.
Following allocation, the warrants are free to be traded on the new
exchange. To contact the warrant agent, please visit:
http://www.computershare.com/. The equivalent options are currently
trading on the ASX under the ticker symbol PGLO. About Progen:
Progen Pharmaceuticals Limited is an Australian-based globally
focused biotechnology company committed to the discovery,
development and commercialization of small molecule therapeutics
primarily for the treatment of cancer. Progen Information: Linton
Burns Progen Pharmaceuticals Limited T: +61 7 3842 3333 E: Noreen
Dillane Progen Pharmaceuticals Limited T: +61 7 3842 3333 E: Media
and Investor Relations Australia: Rebecca Piercy Buchan Consulting
T: +61 2 9237 2800 / 0422 916 422 E: Rebecca Wilson Buchan
Consulting T: +61 417 382 391 E: Media Relations USA: Robert D.
Stanislaro FD T: +1 212-850-5657 E: Investor Relations USA: Evan
Smith FD T: +1 212-850-5606 E: DATASOURCE: Progen Pharmaceuticals
Limited CONTACT: Linton Burns, , or Noreen Dillane, , both of
Progen Pharmaceuticals Limited, +61-7-3842-3333; Media and Investor
Relations Australia: Rebecca Piercy, +61-2-9237-2800, or
0422-916-422, , or Rebecca Wilson, +61-417-382-391, , both of
Buchan Consulting; Media Relations USA: Robert D. Stanislaro of FD,
+1-212-850-5657, ; Investor Relations USA: Evan Smith of FD,
+1-212-850-5606, , all for Progen Pharmaceuticals Limited Web site:
http://www.computershare.com/
Copyright